Share on StockTwits

Cepheid (NASDAQ:CPHD) EVP Warren C. Kocmond, Jr. sold 324 shares of Cepheid stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $38.69, for a total value of $12,535.56. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Shares of Cepheid (NASDAQ:CPHD) traded up 0.16% on Friday, hitting $38.70. The stock had a trading volume of 364,509 shares. Cepheid has a 52-week low of $34.42 and a 52-week high of $55.89. The stock’s 50-day moving average is $44.24 and its 200-day moving average is $47.21. The company’s market cap is $2.708 billion.

Cepheid (NASDAQ:CPHD) last issued its quarterly earnings data on Thursday, July 17th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.16. The company had revenue of $116.50 million for the quarter, compared to the consensus estimate of $115.47 million. During the same quarter in the previous year, the company posted $0.02 earnings per share. The company’s revenue for the quarter was up 21.4% on a year-over-year basis. Analysts expect that Cepheid will post $-0.52 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Cepheid in a research note on Friday. They now have a $41.00 price target on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of Cepheid in a research note on Friday, July 18th. They now have a $54.00 price target on the stock, down previously from $57.00. Finally, analysts at ISI Group cut their price target on shares of Cepheid to $37.00 in a research note on Friday, July 18th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $51.07.

Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.